
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio Inc. is well-positioned for growth as its lead product, Buntanetap, shows potential in modifying disease progression for chronic neurodegenerative diseases like Alzheimer's and Parkinson's. Positive interim results from the Part A trial have demonstrated reduced sAPP levels, and the company plans to initiate a Phase 2 trial in the second half of 2025, indicating a robust developmental pipeline. Additionally, reaching alignment with the FDA regarding their new drug application process enhances the likelihood of successful market entry for their products, suggesting significant future revenue opportunities.
Bears say
Annovis Bio faces significant financial risks, primarily due to its limited cash runway, which raises concerns about potential dilutive capital raising activities. The company’s pipeline, focused on challenging neurodegenerative diseases such as Alzheimer's and Parkinson's, faces high uncertainty, with possible trial failures related to efficacy and safety. Additional risks include the potential lack of FDA approval for its products and anticipated challenges in market performance due to increased competition and pricing pressures, all contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares